Shafique Virani is Chief Business Officer at RECURSION PHARMACEUTICALS, INC. (RXRX). They have made 7 open-market trades across 1 company since 2022, most recently 2024-01-16.
CIK 0001856081
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RXRX | 154,748 | $535K |
Shares reported on the most recent Form 4, priced at the 2024-01-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RXRX | SELL · 10b5-1 | 2024-01-16 | 2024-01-18 | $10.93 | $197K | -1.5% | +26.0% | -25.2% |
| RXRX | SELL · 10b5-1 | 2023-12-15 | 2023-12-19 | $9.60 | $173K | -1.1% | -0.9% | +14.4% |
| RXRX | SELL · 10b5-1 | 2023-11-15 | 2023-11-17 | $6.51 | $117K | -3.1% | +33.7% | +75.8% |
| RXRX | SELL · 10b5-1 | 2023-10-16 | 2023-10-18 | $6.30 | $113K | -14.2% | +13.9% | +73.8% |
| RXRX | SELL · 10b5-1 | 2023-09-15 | 2023-09-19 | $8.66 | $156K | -9.3% | -28.2% | +12.1% |
| RXRX | SELL · 10b5-1 | 2023-08-15 | 2023-08-17 | $9.25 | $167K | -1.2% | +1.2% | -16.8% |
| RXRX | SELL · 10b5-1 | 2023-07-25 | 2023-07-27 | $14.36 | $574K | -11.6% | -34.1% | -57.1% |
| RXRX | SELL · 10b5-1 | 2023-07-17 | 2023-07-19 | $12.73 | $764K | -8.1% | -44.1% | -57.6% |
| RXRX | SELL · 10b5-1 | 2023-06-15 | 2023-06-20 | $9.54 | $572K | -16.4% | +65.7% | -2.3% |
| RXRX | SELL · 10b5-1 | 2023-06-01 | 2023-06-05 | $8.79 | $534K | +11.2% | -12.8% | +4.1% |
| RXRX | SELL | 2023-02-15 | 2023-02-17 | $8.34 | $140K | +1.3% | -8.2% | -30.8% |
| RXRX | SELL | 2023-01-17 | 2023-01-19 | $9.16 | $92K | -3.6% | -10.8% | -31.0% |
| RXRX | SELL | 2022-12-15 | 2022-12-19 | $8.85 | $89K | +2.1% | +18.4% | -3.8% |
| RXRX | SELL | 2022-11-15 | 2022-11-17 | $12.31 | $246K | -16.0% | -32.0% | -24.6% |
| RXRX | SELL | 2022-10-14 | 2022-10-18 | $10.92 | $218K | +2.0% | +0.5% | -15.5% |
| RXRX | SELL | 2022-09-15 | 2022-09-16 | $13.37 | $134K | +11.4% | -0.6% | -19.1% |
| RXRX | SELL | 2022-08-16 | 2022-08-17 | $12.61 | $378K | -8.4% | -3.0% | +6.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.